GlassScriptPhysician profile
Anwar Khurshid
NPI 1922000488
$1,221.31
in general payments reported to CMS, 2019-2025
32 companies · $457 in 2025
The $457 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $436 · 2021: $61.03 · 2022: $55.28 · 2023: $39.36 · 2024: $172 · 2025: $457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $652 · Education: $16.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $652.24 |
| Education | $16.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $162.82 | 2019-2025 | Opdivo, Camzyos |
| Celgene Corporation | $161.12 | 2024-2025 | Reblozyl, Opdualag |
| Novartis Pharmaceuticals Corporation | $143.10 | 2019-2025 | |
| Abbvie INC. | $63.93 | 2023-2025 | |
| Array Biopharma INC | $61.84 | 2024-2025 | Braftovi, Xalkori, Mektovi |
| Genentech USA, INC. | $54.54 | 2019-2025 | Polivy |
| Lilly USA, LLC | $51.25 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $47.71 | 2019-2025 | Enhertu |
| Beone Medicines USA, INC. | $40.41 | 2025 | Tevimbra |
| Regeneron Healthcare Solutions, INC. | $37.35 | 2025 | Libtayo |
| Acrotech Biopharma INC. | $35.91 | 2021-2022 | |
| Astellas Pharma US INC | $31.99 | 2019 | |
| Janssen Biotech, INC. | $28.44 | 2019 | |
| Aveo Pharmaceuticals, INC. | $26.81 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.17 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $24.43 | 2025 | Jemperli, Zejula |
| Exelixis INC. | $23.91 | 2025 | Cabometyx |
| Genzyme Corporation | $23.13 | 2019 | |
| Pfizer INC. | $22.24 | 2019 | |
| Agios Pharmaceuticals, INC. | $20.13 | 2019 | |
| Karyopharm Therapeutics INC. | $18.49 | 2024 | Xpovio |
| Takeda Pharmaceuticals U.S.A., INC. | $16.40 | 2025 | Fruzaqla |
| Merck Sharp & Dohme LLC | $16.27 | 2019 | |
| Sirtex Medical INC | $14.69 | 2019 | |
| Emd Serono, INC. | $14.56 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $13.74 | 2019 | |
| Incyte Corporation | $13.53 | 2019 | |
| Amgen INC. | $12.93 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Clovis Oncology, INC. | $2.55 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anwar Khurshid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.